---
title: "Merck Sees $70B Revenue Potential From New Growth Drivers by Mid-2030s"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/272391796.md"
description: "Pharma giant Merck (MRK) aims for $70 billion in revenue from new growth drivers by the mid-2030s, up from a previous estimate of $50 billion. This strategy is in response to the impending patent expiration of its cancer drug Keytruda in 2028. CEO Robert Davis expressed confidence in achieving $50 billion by the early 2030s, driven by 10 major programs. Merck anticipates significant contributions from cardiometabolic, respiratory, and infectious disease treatments. The company is also exploring strategic acquisitions, including a potential $28-$32 billion deal for Revolution Medicines."
datetime: "2026-01-13T09:54:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/272391796.md)
  - [en](https://longbridge.com/en/news/272391796.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/272391796.md)
---

# Merck Sees $70B Revenue Potential From New Growth Drivers by Mid-2030s

Pharma giant Merck (MRK) is targeting $70 billion in revenue from new growth drivers by the mid-2030s, as the company accelerates the launch of new drugs to mitigate the impact of the loss of business from the patent expiration of its blockbuster cancer drug Keytruda in 2028. This new target marks a step up from the company's previously announced estimate of $50 billion in new growth opportunities. Merck discussed its new target and growth drivers at the 44th annual J.P. Morgan Healthcare Conference held on Monday.

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

## **Merck Seeks to Boost Business via Organic Growth and Strategic Deals**

During the event, Merck's CEO Robert Davis expressed confidence that the company would achieve $50 billion of its $70 billion target by the early 2030s. Davis added that the company's optimism is based on 10 major programs that make up 70% of the $70 billion estimate. Merck views all these programs as multibillion-dollar opportunities. In fact, four of the 10 programs are either already launched or have positive Phase III data, with the remaining expected to have important Phase III readouts over the next 12 to 18 months.

According to _Reuters_, Merck expects cardiometabolic and respiratory treatments to contribute nearly $20 billion in sales, up from its previous ⁠forecast of $15 ​billion. Also, infectious disease drugs are estimated to generate about $15 billion, compared with the earlier projection of $5 billion.

Additionally, the company is open to further strategic acquisitions. According to _Bloomberg_, CEO Davis said, "We are not limited from a balance sheet — it's more where do we see strategic opportunity."

The CEO's comments come amid reports that Merck is in talks to buy cancer drugmaker Revolution Medicines (RVMD). Citing sources, the _Financial Times_ reported last week that Merck is considering acquiring Revolution Medicines for $28 billion to $32 billion.

## **Is Merck Stock a Buy, Sell, or Hold?**

Currently, Wall Street has a Moderate Buy consensus rating on Merck stock based on 11 Buys and five Holds. The average MRK stock price target of $119.53 indicates 9.5% upside potential.

### Related Stocks

- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)

## Related News & Research

- [BUZZ-PREVIEW: Merck gains ahead of quarterly earnings report](https://longbridge.com/en/news/284644343.md)
- [Merck posts quarterly loss due to Cidara charge, sales rise 5%](https://longbridge.com/en/news/284745991.md)
- [Onco-Innovations Announces Inka Health Collaborative Research to Advance Oncology Evidence Generation | ONNVF Stock News](https://longbridge.com/en/news/285274936.md)
- [BUZZ-Replimune falls after FDA's Makary defends decision on cancer drug](https://longbridge.com/en/news/285229479.md)
- [09:44 ETConverge Bio uses ConvergeAB to improve popular cancer treatment with a single prompt](https://longbridge.com/en/news/285081995.md)